Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

Groundbreaking Results of CD7-Targeted CAR-T Therapy for T-ALL and T-LBL

2024-06-18

A recent clinical trial has demonstrated significant advances in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) using CD7-targeted chimeric antigen receptor (CAR) T cell therapy. The study, conducted by a team from Hebei Yanda Lu Daopei Hospital and Lu Daopei Institute of Hematology, involved 60 patients who received a single dose of naturally selected anti-CD7 CAR (NS7CAR) T cells.

The trial results are highly encouraging. By day 28, 94.4% of patients achieved deep complete remission (CR) in bone marrow. Additionally, among the 32 patients with extramedullary disease, 78.1% showed a positive response, with 56.3% achieving complete remission and 21.9% achieving partial remission. The two-year overall survival and progression-free survival rates were 63.5% and 53.7%, respectively.

CAR-T Study.png

This innovative therapy is noteworthy for its manageable safety profile, with cytokine release syndrome occurring in 91.7% of patients (mostly grade 1/2), and neurotoxicity observed in 5% of cases. Furthermore, the study found that patients who proceeded with consolidation transplants after achieving CR had significantly higher progression-free survival rates compared to those who did not.

Our company is also exploring the potential of CD7 CAR-T cell therapy with our proprietary product, aiming to contribute to the advancement of treatments for T-cell malignancies.

These findings underscore the potential of CD7-targeted CAR-T cell therapy to offer new hope for patients with refractory or relapsed T-ALL and T-LBL, marking a significant milestone in the ongoing battle against these challenging diseases.